Facebook Twitter LinkedIn YouTube Instagram

To navigate the following site navigation expect to utilize the tab key to move through items sequentially. The spacebar or enter keys can be utilized to interact with items that open sub-navigation.

The next tab will be the search box toggle. Hit enter to open the search, focus will automatically shift to the search bar. Type a letter into the search input and suggested results will appear.

Drug

LIQ861 (YUTREPIA)

Status:

To Patients

Condition:

Other ILD

Intervention Type:

Inhaled Drug

Funder Type:

Industry

Drug Details

YUTREPIA is an investigational, inhaled dry-powder formulation of treprostinil delivered through a convenient, low-effort, palm-sized device.

Study Purpose

Study LTI-401 is an open-label, multicenter study that will evaluate the safety and tolerability of LIQ861 in subjects who have WHO Group 1 & 3 PH. The exploratory objectives of the study are to assess the effects of LIQ861 on exercise capacity, functional class, relevant biomarkers, and imaging assessments.

Find a Clinical Trial